BNP Paribas Financial Markets Has $201,000 Stock Position in Harvard Bioscience, Inc. (NASDAQ:HBIO)

BNP Paribas Financial Markets lowered its holdings in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 28.9% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 74,676 shares of the medical instruments supplier’s stock after selling 30,339 shares during the period. BNP Paribas Financial Markets’ holdings in Harvard Bioscience were worth $201,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in HBIO. Assenagon Asset Management S.A. grew its holdings in Harvard Bioscience by 193.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock worth $649,000 after acquiring an additional 150,218 shares during the period. Acuitas Investments LLC lifted its holdings in shares of Harvard Bioscience by 24.8% in the second quarter. Acuitas Investments LLC now owns 407,343 shares of the medical instruments supplier’s stock valued at $1,161,000 after purchasing an additional 80,827 shares in the last quarter. Gabelli Funds LLC purchased a new stake in shares of Harvard Bioscience in the second quarter valued at about $128,000. Renaissance Technologies LLC lifted its position in shares of Harvard Bioscience by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 745,278 shares of the medical instruments supplier’s stock worth $2,124,000 after buying an additional 42,800 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Harvard Bioscience by 13.0% during the second quarter. Bank of New York Mellon Corp now owns 274,635 shares of the medical instruments supplier’s stock valued at $783,000 after acquiring an additional 31,505 shares during the last quarter. 80.87% of the stock is currently owned by institutional investors and hedge funds.

Harvard Bioscience Trading Down 0.9 %

NASDAQ HBIO opened at $2.14 on Tuesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.06 and a quick ratio of 0.91. The stock has a market capitalization of $93.34 million, a price-to-earnings ratio of -6.48 and a beta of 1.27. Harvard Bioscience, Inc. has a one year low of $1.99 and a one year high of $5.56. The business’s fifty day moving average is $2.32 and its 200-day moving average is $2.71.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.